. 2020 Nov 13;17:176. doi: 10.1186/s12985-020-01447-2

Table 3.

Drug resistance conferring mutations from the current study

Accession number	Mutations	Drug resisted	HBsAg sero status
MT185643	Y126H	Adefovir dipivoxil(ADV)	Negative
	M129L	Lamivudine
	V163I	Lamivudine
MT185642	Y126H	Adefovir dipivoxil(ADV)	Negative
	M129L	Lamivudine
	V163I	Lamivudine
MT185644	Y126H	Adefovir dipivoxil(ADV)	Positive
	M129L	Lamivudine
	V163I	Lamivudine
MT185645	Y126H	Adefovir dipivoxil(ADV)	Negative
	M129L	Lamivudine
	V163I	Lamivudine
	S202G	Entecavir & Lamivudine
MT185646	Y126H	Adefovir dipivoxil(ADV)	Negative
	M129L	Lamivudine
	V163I	Lamivudine
MT185647	Y126H	Adefovir dipivoxil(ADV)	Negative
	M129L	Lamivudine
	V163I	Lamivudine
MT185648	M129L	Lamivudine	Negative
MT185648	V163I	Lamivudine	Negative
MT185649	M129L	Lamivudine	Positive
MT185649	V163I	Lamivudine	Positive
MT185650	M129L	Lamivudine	Negative
	V163I,	Lamivudine
	A181T	Lamivudine (zeffix), Adefovir(Hepsera), Telbivudine(Tyzeka and Sebivo)

These mutations were identified using two online tools Geno2Pheno HBV database (HBVdb) (https://hbv.geno2pheno.org/) and HBVseq program from HIV Stanford database (https://hivdb.stanford.edu/HBV/HBVseq/development/HBVseq.html). The mutations are listed for each of the sample where they occurred